Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Surge In TXMD: Key Developments

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 10/18/2025, 12:20 pm ET | 5 min
Surge In TXMD: Key Developments Thumbnail

In this article Last trade Oct, 17 7:43 PM

  • TXMD+11.96%
    TXMD - NYSETherapeuticsMD Inc.
    $1.17+0.13 (+11.96%)
    Volume:  8.77M
    Float:  8.35M
    $1.05Day Low/High$1.70

TherapeuticsMD Inc.’s stocks have been trading up by 12.92 percent, driven by positive sentiment and market confidence.

Healthcare industry expert:

Analyst sentiment – neutral

  1. Market Position & Fundamentals: TXMD is navigating challenging circumstances, evident in its mixed financial metrics. With a notably high gross margin of 100%, the company shows strong product profitability after accounting for cost of goods sold. However, this is overshadowed by its pretax profit margin of -126.1%, highlighting substantial operational inefficiencies. Nonetheless, a profitability improvement has been marked by its EBITDA margin of 59.3%. The net income standing at $551,000 for the latest report period suggests a resilient, albeit delicate, financial recovery. The enterprise value at about $15 million coupled with a price-to-sales ratio of 4.73 signifies moderate market valuation, but potential investor apprehension is suggested by a significant negative return on equity of -1355.64%. The overall financial health requires cautious optimism backed by strategic realignment and effective cost management to enhance its market position.

  2. Technical Analysis & Trading Strategy: TXMD’s weekly price data indicates a volatile trading pattern. The price opening at $1.04 and closing at $1.18 across the week displays investor decisive buy-in, especially marked by the substantial jump on October 17, 2025. The breakout above $1.12 signals a bullish engulfing pattern, presenting a significant upward force. Given the volume surge coinciding with price elevation on October 17, it suggests acquiring momentum. A trading strategy here involves buying on dips towards the support at $1.05 while setting a stop-loss just below this level, capitalizing on the upward trend with a target of $1.26 in the near term, given previous resistance at this peak.

  3. Catalysts & Outlook: Recent developments lacking significant news catalysts imply market responses are more technically driven at present. When compared to the broader Healthcare and Pharmaceuticals sectors, TXMD’s recent performance appears comparatively timid despite its operational restructuring efforts. While sector benchmarks emphasize innovation and scale efficiency, TXMD relies on refining financial management to capture market share. Provided that TXMD can sustain above the $1.12 resistance turned support, I foresee steady growth potential with a cautious bullish outlook. Immediate price target should focus around the recent high of $1.26, potentially prompting upward traction if general market conditions support.

Candlestick Chart

Weekly Update Oct 13 – Oct 17, 2025: On Saturday, October 18, 2025 TherapeuticsMD Inc. stock [NASDAQ: TXMD] is trending up by 12.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TherapeuticsMD Inc. has recently shown improved financial health, evident from the latest stock activity and key financial figures. The close price on October 17, 2025, closed at $1.18, reflecting an optimistic rise from previous days, driven by strategic business moves and external market influences. The revenue, although modest at $1.76M, reveals a shift towards better financial management despite historical challenges. Profitability, marked by a gross margin of 100%, suggests operations have efficiently managed costs, even as the company deals with varying profit margins across the board. In the financial strength arena, a current ratio of 2.9 places the company in a firm liquidity position, indicating it can comfortably cover its debts in the short term.

More Breaking News

Recent cash flow dynamics also reveal improvement: cash inflow activities have bolstered the reserve from $5.74M to $6.06M by mid-2025. This financial staunchness stems from prudent capital management, as current assets surpass liabilities significantly. The management’s effectiveness ratios show mixed feedback but underscore the potential for strategic recalibration to boost operational efficiencies. These indicators may allude to a forecast of steady growth, contingent on capitalizing on revenue generation opportunities.

Conclusion

In wrapping up, TherapeuticsMD Inc. exhibits resilience and keen business acumen as reflected in its progressive stock performance. The positive movement underscores both market confidence and strategic revitalization efforts merging towards stability. The future presents an opportunity for TherapeuticsMD to capitalize on its strengthened balance sheet and manage profitability better. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” As trading confidence increases, continued operational focus and strategic maneuvers will be pivotal in maintaining growth momentum. A tailored approach prioritizing liquidity and cost management can be the key to further financial improvements and broader market traction.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

In this article (YTD Performance)

  • TXMD+45.35%
    TXMD - NYSETherapeuticsMD Inc.
    $1.17+0.13 (+11.96%)
    Volume:  8.77M
    Float:  8.35M
    $1.05Day Low/High$1.70

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications